Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis : 10 years of real-world data in the Swedish National Psoriasis Register
Hjalte, F. ; Carlsson, K. S. LU
and Schmitt-Egenolf, M.
(2018)
In British Journal of Dermatology
178(1).
p.245-252
- Abstract
Background: Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real-world data on the effectiveness of biological treatment. Objectives: To analyse the long-term real-world outcome data of patients who are biologically naïve with moderate-to-severe psoriasis after switching to biological treatment. Methods: An observational study of patients who are biologically naïve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI)... (More)
Background: Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real-world data on the effectiveness of biological treatment. Objectives: To analyse the long-term real-world outcome data of patients who are biologically naïve with moderate-to-severe psoriasis after switching to biological treatment. Methods: An observational study of patients who are biologically naïve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) values were analysed at 3-5 months, 6-11 months and at least once after ≥ 1 year, up to 9 years after the switch to biological treatment. Results: In total, 583 patients fulfilled the inclusion criteria. Of these, 399, 395 and 373 patients had observed outcome data beyond 1 year on the PASI, DLQI and EQ-5D, respectively, and 164, 168 and 152, respectively, were observed in at least three time periods after the switch. Significant (P < 0·01) improvement in PASI, DLQI and EQ-5D scores was observed 3-5 months after the switch and sustained under the whole observation period. The mean PASI, DLQI and EQ-5D changed from 13·5 ± 9·1, 9·0 ± 8·1 and 0·74 ± 0·22, respectively, before the switch, to 4·0 ± 3·5, 3·7 ± 4·7 and 0·79 ± 0·21, respectively, 1-5 years after the switch. Conclusions: Biological treatment, as used in clinical practice, shows a stable long-term effectiveness in all the measured dimensions, PASI, DLQI and EQ-5D.
(Less)
- author
- Hjalte, F.
; Carlsson, K. S.
LU
and Schmitt-Egenolf, M.
- organization
- publishing date
- 2018
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Dermatology
- volume
- 178
- issue
- 1
- pages
- 245 - 252
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:28644904
- scopus:85040172867
- ISSN
- 0007-0963
- DOI
- 10.1111/bjd.15757
- language
- English
- LU publication?
- yes
- id
- 9136d5ff-0168-4ff6-a979-9e1949c605de
- date added to LUP
- 2018-01-23 15:22:48
- date last changed
- 2024-03-31 23:58:10
@article{9136d5ff-0168-4ff6-a979-9e1949c605de,
abstract = {{<p>Background: Few studies have analysed the long-term effects of biological treatment in psoriasis. PsoReg, the Swedish national register for systemic psoriasis treatment, started in 2006 and now includes 10 years of real-world data on the effectiveness of biological treatment. Objectives: To analyse the long-term real-world outcome data of patients who are biologically naïve with moderate-to-severe psoriasis after switching to biological treatment. Methods: An observational study of patients who are biologically naïve with at least one registration of outcome before switching to biological treatment while included in PsoReg and at least one follow-up visit. Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and EuroQol-5D (EQ-5D) values were analysed at 3-5 months, 6-11 months and at least once after ≥ 1 year, up to 9 years after the switch to biological treatment. Results: In total, 583 patients fulfilled the inclusion criteria. Of these, 399, 395 and 373 patients had observed outcome data beyond 1 year on the PASI, DLQI and EQ-5D, respectively, and 164, 168 and 152, respectively, were observed in at least three time periods after the switch. Significant (P < 0·01) improvement in PASI, DLQI and EQ-5D scores was observed 3-5 months after the switch and sustained under the whole observation period. The mean PASI, DLQI and EQ-5D changed from 13·5 ± 9·1, 9·0 ± 8·1 and 0·74 ± 0·22, respectively, before the switch, to 4·0 ± 3·5, 3·7 ± 4·7 and 0·79 ± 0·21, respectively, 1-5 years after the switch. Conclusions: Biological treatment, as used in clinical practice, shows a stable long-term effectiveness in all the measured dimensions, PASI, DLQI and EQ-5D.</p>}},
author = {{Hjalte, F. and Carlsson, K. S. and Schmitt-Egenolf, M.}},
issn = {{0007-0963}},
language = {{eng}},
number = {{1}},
pages = {{245--252}},
publisher = {{Wiley-Blackwell}},
series = {{British Journal of Dermatology}},
title = {{Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis : 10 years of real-world data in the Swedish National Psoriasis Register}},
url = {{http://dx.doi.org/10.1111/bjd.15757}},
doi = {{10.1111/bjd.15757}},
volume = {{178}},
year = {{2018}},
}